Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
[email protected]
SOURCE: Protagonist Therapeutics
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
KPMG LLP names new line of business heads
KPMG LLP, the US member company of KPMG International, has appointed new leaders across several of its business divisions. The changes are effective immediately. Manish Madhavani will oversee financial services, while Chris Marston takes on responsibility for government and healthcare. Dave Neuenhaus has been selected to lead asset management and private equity. Heather Rice has been appointed to lead the products division, and Chad Seiler will head the technology, media and telecom segment. Several members of the executive team will remain in their current roles. Maureen Davenport continues as chief corporate affairs officer and Kelle Fontenot stays on as chief digital officer. Marc Macaulay retains his position as chief financial officer and Elena Richards remains in charge of culture and inclusion. These appointments follow earlier announcements regarding national managing partners, principals and the company's chief strategy officer. The leadership group will be involved in supporting the company's strategy execution. KPMG LLP operates as part of the global KPMG network, which is active in 142 countries and territories and employs more than 275,000 people. Each company in the network is legally distinct. In June this year, KPMG International launched KPMG Workbench, an AI platform aimed at scaling the global adoption and integration of AI. KPMG Workbench will act as the backbone of the company's client delivery platforms including KPMG Digital Gateway, KPMG Velocity and KPMG Clara. The introduction of KPMG Workbench is part of the company's multibillion dollar investment in AI and agentic transformation. "KPMG LLP names new line of business heads" was originally created and published by International Accounting Bulletin, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Recent IPO Stock Gains Suggest a 'Spillover' Effect Could Boost Upcoming Debuts
Key Takeaways This year's cohort of new issues are popping on their first trading day, with some closing at more than double their IPO prices. Well-received IPOs tend to spawn other pops, University of Florida business professor Jay Ritter says. The median first-day performance of U.S. IPOs that raised $100 million or more was about 19% so far this year, the highest since 2020, according to Renaissance demand for initial public offerings is putting the shine in 2025's newest stocks. The median first-day performance of US IPOs—those that raised at least $100 million—was about 19% so far this year, the highest since 2020's median of 33%, according to Renaissance Capital, a provider of pre-IPO research and related ETFs. The firm's index of larger new listings that have been public for less than three years, tracked by the US IPO ETF (IPO), was up 12% through the Friday's close, ahead of the S&P 500's 8.6% gain. Firefly Aerospace (FLY), WhiteFiber (WYFI), and HeartFlow (HTFL), which priced last week, were included in those figures. Hot first-day performance can effect subsequent deals in what University of Florida business professor Jay Ritter calls a "spillover" effect. Companies waiting in the wings to go public could bask in the afterglow of NewsMax (NMAX), FatPipe (FATN), Circle Internet Group (CRCL), AIRO Group Holdings (AIRO) and Figma (FIG), all of which doubled their IPO prices, or better, over their respective trading debuts. More IPOs are on the way. Crypto exchange and CoinDesk owner Bullish is set to debut today under the ticker "BLSH." Tickets provider StubHub, which delayed its IPO plans following Liberation Day stock volatility, is reportedly kicking off its roadshow after Labor Day and will make its public debut in late September. There is no crystal ball for how well a new stock will do, but the ones that tend to outperform have things in common. "The vast majority of those with big run-ups are venture-capital backed. Lots are tech stocks. They're hard to value," Ritter told Investopedia, citing examples like Netscape in 1995 or Airbnb (ABNB) in 2020. Of the top 10 VC exits via US IPOs in value terms, which include Figma (FIG), Chime Financial (CHYM), and Circle (CRCL), according to PitchBook data, only one didn't pop on Day 1: CoreWeave (CRWV), which priced its IPO also under its marketed range. Its shares have subsequently risen almost 250% since its March debut. Figma, which went on a blistering rally as soon as it listed on July 31, has since declined about 25%. New stocks generally experience mean reversion. "Those that double or more on the first day have average long-term returns below IPOs that had less-than-enthusiastic first-day receptions," according to Ritter, who defines "long-term" as three years. The issue with the companies that tend to rocket up on their trading day, is that they then have a very high price-to-sales ratio. "It's difficult for a company to meet expectations when there's so much optimism built into the price," he said. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Bessent Sees Nvidia, AMD China Agreements as a Model for Others
(Bloomberg) -- Treasury Secretary Scott Bessent said the recent deal to allow Nvidia Corp. and Advanced Micro Devices Inc. to resume lower-end AI chip sales to China, on the condition they give the US government a 15% cut of the related revenue, could serve as a model for others. 'I think we could see it in other industries over time,' Bessent said Wednesday in a television interview on . 'Right now, this is unique, but now that we have the model and the beta test, why not expand it?' Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' New York Warns of $34 Billion Budget Hole, Biggest Since 2009 Crisis Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets Bessent credited President Donald Trump with the 'very unique solution' of allowing Nvidia to expand in China and become a bellwether for Chinese technology, with the US taxpayer getting 'a share of' the reward. The revenue the Treasury receives from the arrangement will go to pay down debt, he said. 'If we could make a substantial debt' repayment, that would then allow for discussions about a program of sending money to taxpayers, he also said. Asked about reporting that China is urging its companies to avoid the Nvidia H20 processors now allowed for its market, Bessent said 'sure, we can discuss that' with the Chinese. 'But it also tells me that they are worried about the Nvidia chips becoming the standard in China.' China Talks On Tuesday, Bessent said that he'd be meeting again with his Chinese counterparts 'within the next two or three months,' speaking on Fox Business. He dismissed the possibility of China emulating other US trading partners in winning tariff relief in return for boosting investments in the US. When asked if China could make pledges worth billions of dollars like Japan, South Korea and the EU have as part of their trade agreements, Bessent said 'my sense is no because a lot of the buyout or the funds from the buyout are going to go to critical industries that we need to reshore and a lot of those need to be reshored away from China.' Whether the industry was semiconductors, rare-earth magnets, pharmaceuticals or steel, 'my sense is that isn't what will happen,' Bessent said in an interview with Fox Business on Tuesday. Tech and AI have been among the most high profile of areas of competition between the world's two biggest economies. President Donald Trump has extended a pause of higher tariffs on Chinese goods for another 90 days into early November, a move that stabilized trade ties between the world's two largest economies while they try to forge an agreement. Chinese companies in sectors such as electric vehicles have opened factories abroad to access new markets, a move that could also help them skirt US tariffs. He also indicated that Washington wanted to see measures from China over an extended period to stem the flow of chemicals used to make fentanyl before lowering duties Trump put in place over the issue. 'We will need to see months, if not quarters, if not a year, of progress on that before I could imagine those tariffs coming down,' he said. --With assistance from Philip Glamann. (Updates with comments from Bessent's Bloomberg TV interview.) Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Dubai's Housing Boom Is Stoking Fears of Another Crash The Social Media Trend Machine Is Spitting Out Weirder and Weirder Results A $340 Million New York Office Makeover Is Converting Boardrooms to Bedrooms ©2025 Bloomberg L.P. Sign in to access your portfolio
